Alamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral Presentations

Résumé détaillé
Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that data ...
Fremont, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that data generated with its NULISA™ precision proteomic platform will be featured in 46 presentations, including 10 oral presentations, at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place November 16 to 19, 2026, in Boston.
The presentations come from researchers at academic centers, clinical research institutes and biopharmaceutical companies in the United States, Europe and Asia. Together they show NULISA being used at each stage of Alzheimer’s research, from identifying who is at risk and enrolling the right patients in clinical trials to measuring how patients respond to treatment.
Since its commercial launch in January 2024, Alamar’s NULISA technology has been cited in hundreds of research publications worldwide, including studies advancing the early detection, diagnosis, monitoring and treatment of Alzheimer’s disease.
“Given the advances in blood-based biomarkers for diagnosing Alzheimer’s, research is shifting toward treatment, and that shift depends on measuring many proteins in blood with enough sensitivity to see small changes over time,” said Yuling Luo, PhD, founder, CEO and chair of Alamar Biosciences. “This year’s CTAD presentations show researchers using NULISA to screen patients, enrich clinical trials and follow therapeutic response, often in the same study. The breadth of this work reinforces NULISA’s position as the leading multiplex platform in Alzheimer’s research. We are grateful to our collaborators for this work and for what it means for the patients who will benefit from it.”
“Blood biomarkers have transformed how we diagnose Alzheimer’s disease and conduct clinical trials. With the development of an ultrasensitive singleplex assay for plasma eMTBR-tau, we are moving closer to characterizing the two fundamental pathological…
Début de l'article, extrait de Toronto Star. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.thestar.com)


